In our study, with the use of neoadjuvant therapy and trastuzumab, the pCR rate of LNs was higher than that in previous studies29,30, suggesting that dose-dense chemotherapy may be more beneficial for LN-positive patients with HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.